RxDoctor Payments DataLook up a doctor →

Javier Roman Gonzalez, MD

Clinical Cardiac Electrophysiology · San Antonio, TXNPI 1427058643

Payments from drug & device makers

$178,575in general payments, 2019–2025

Across 356 payments — averaging $501.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$60K
  • Cardiofocus, Inc.$42K
  • Abbott$31K
  • Biosense Webster, Inc.$22K
  • Boston Scientific$15K
  • Johnson & Johnson$5K
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$21,27746%
  • Speaking & faculty fees$5,45012%
  • Travel & lodging$12,47727%
  • Food & beverage$6,91315%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$178,575 in reported general payments places this provider in the 80th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$623,304
Medicare patients
911
Services billed
7,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban274$331,754
EliquisApixaban227$273,981
SotalolSotalol Hcl656$12,278
Metoprolol Succinate255$5,030
Flecainide Acetate98$3,399
Amiodarone Hcl140$2,628
Propafenone Hcl ErPropafenone Hcl12$2,458
Carvedilol252$2,161
Mexiletine Hcl19$1,906
Propafenone Hcl35$1,535
ClopidogrelClopidogrel Bisulfate104$1,493
Diltiazem 24hr Er (Cd)Diltiazem Hcl75$1,483
Propranolol Hcl ErPropranolol Hcl21$1,156
Digoxin35$902
Omeprazole69$769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$5,220$331,754274 claims
PfizerEliquis$70$273,981227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →